Summary: COMPREHENSIVE SDSU-UCSD CANCER CENTER PARTNERSHIP
NCI Grants #U54 CA132384 and #U54 CA132379
Project Period: 9/1/2008 8/31/2013
Funded Projects 2009
OPTIMIZED NANOPARTICLE VACCINES FOR PROSTATE CANCER
Minority Institution Co-Leader Cancer Center Co-Leader
Douglas Grotjahn, Ph.D.
Dept. of Chemistry
Boris R. Minev, M.D.
Dept. of Family & Preventative Medicine
Among the body's potential defenses are white blood cells called cytotoxic T lymphocytes
(CTL). CTL can recognize and kill cancer cells, but only if they see complexes of protein
fragments (peptides) attached to special molecules on the surface of the cancer cells. Several
recent reports demonstrated the presence of anti-tumor CTL in blood from patients with brain
tumors. It was also found that a protein called surviving exists in most prostate cancers.
We found recently several small pieces (peptides) derived from the protein surviving on the